BNP Paribas Financial Markets
ITOS

BNP Paribas Financial Markets’s iTeos Therapeutics ITOS Stock Holding History

BNP Paribas Financial Markets’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,864
Closed -$68.4K – 5667
2025
Q2 		$68.4K Buy
6,864
+58
+0.9% +$467 ﹤0.01% 4143
2025
Q1 		$40.6K Sell
6,806
-53,273
-89% -$391K ﹤0.01% 4353
2024
Q4 		$461K Buy
+60,079
New +$516K ﹤0.01% 3357
2022
Q4 		– Sell
-47,064
Closed -$897K – 4322
2022
Q3 		$897K Buy
+47,064
New +$1.08M ﹤0.01% 2573

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BNP Paribas Financial Markets's ITOS Position: Q3 2025 in Review

BNP Paribas Financial Markets sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 6,864 shares — an estimated $68.4K sold.

BNP Paribas Financial Markets first reported a position in ITOS in Q3 2022 and held it in 4 quarters. The position peaked at $897K in Q3 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • BNP Paribas Financial Markets reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 6,864 iTeos Therapeutics shares in Q3 2025, an estimated $68.4K.
  • BNP Paribas Financial Markets first reported a position in iTeos Therapeutics in Q3 2022 and held it in 4 quarters.
  • BNP Paribas Financial Markets's iTeos Therapeutics position peaked at $897K in Q3 2022.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.